Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron

Jan 12 2022

• By Scrip Team

J.P. Morgan Daily Notebook 2022 Day 2 — • Source: Alamy

Related Content

Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align

Jan 12 2022

BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA

Jan 05 2022

BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?

Nov 10 2021

Comirnaty Gives Booster Shot To Pfizer Q3 Sales

Nov 02 2021

FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands

Sep 01 2021

Sanofi Scores Clinical Win In Sixth Disease For Dupixent

Oct 22 2021

Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

Jan 12 2022

Related Companies

GSK plc

Vir Biotechnology, Inc.

Sanofi

Tidal Therapeutics

Kymab Ltd.

Translate Bio

Kadmon Holdings, Inc.

ORIGIMM Biotechnology

Amunix Pharmaceuticals, Inc.

BioNTech SE

Pfizer Inc.

Roche Holding AG

Eli Lilly and Company

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

BioPharmaceutical

More from Archive

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.